Alpha Cognition

Moat components and scores: Intangible assets 65/100 (U.S. composition‑of‑matter patent on benzgalantamine tablets through 2044, plus recently issued U.S. patent claims on dosing and a TBI method of use to about 2045; ZUNVEYL brand is early).

Switching costs 35/100 (AChEI class switching is common; LTC workflows and payer formularies can create some friction once established). Network effects 0/100 (none). Cost advantage 30/100 (branded product competes with low‑cost generics; manufacturing is outsourced with high product gross margins but that is not a customer moat).

Efficient scale 40/100 (focus on LTC psychiatry and nursing homes with a 60‑person field team can create localized density, but rivals can deploy similar teams).

Weighted blend ≈45/100. Key risks to moat durability: (1) label still requires dose titration like legacy galantamine which tempers clear differentiation; (2) payers may impose step‑therapy to cheaper generics absent robust real‑world evidence; (3) IP may face challenges over time despite recent issuances.

Offsetting positives: growing Medicare Part D access, multiple 2026 evidence reads (BEACON/CONVERGE/RESOLVE), and APAC partner leverage could widen perceived differentiation if data show superior tolerability/behavioral outcomes.